Bryan C Fuchs
Overview
Explore the profile of Bryan C Fuchs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
98
Citations
3575
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Sojoodi M, Erstad D, Barrett S, Salloum S, Zhu S, Qian T, et al.
Cell Mol Gastroenterol Hepatol
. 2022 Jan;
13(5):1483-1509.
PMID: 35093588
Background & Aims: During liver fibrosis, tissue repair mechanisms replace necrotic tissue with highly stabilized extracellular matrix proteins. Extracellular matrix stabilization influences the speed of tissue recovery. Here, we studied...
12.
Qian T, Fujiwara N, Koneru B, Ono A, Kubota N, Jajoriya A, et al.
Gastroenterology
. 2021 Dec;
162(4):1210-1225.
PMID: 34951993
Background & Aims: There is a major unmet need to assess the prognostic impact of antifibrotics in clinical trials because of the slow rate of liver fibrosis progression. We aimed...
13.
Green J, Osterhout R, Klova A, Merkwirth C, McDonnell S, Zavareh R, et al.
Mol Ther Oncolytics
. 2021 Dec;
23:547-559.
PMID: 34938855
Although anti-tumor activities of type I interferons (IFNs) have been recognized for decades, the molecular mechanisms contributing to clinical response remain poorly understood. The complex functions of these pleiotropic cytokines...
14.
Crouchet E, Bandiera S, Fujiwara N, Li S, El Saghire H, Fernandez-Vaquero M, et al.
Nat Commun
. 2021 Sep;
12(1):5525.
PMID: 34535664
Chronic liver disease and hepatocellular carcinoma (HCC) are life-threatening diseases with limited treatment options. The lack of clinically relevant/tractable experimental models hampers therapeutic discovery. Here, we develop a simple and...
15.
Waghorn P, Ferreira D, Erstad D, Rotile N, Masia R, Jones C, et al.
Sci Rep
. 2021 Sep;
11(1):18167.
PMID: 34493776
No abstract available.
16.
Fujiwara N, Kobayashi M, Fobar A, Hoshida A, Marquez C, Koneru B, et al.
Med
. 2021 Jul;
2(7):836-850.e10.
PMID: 34318286
Background: Accurate non-invasive prediction of long-term hepatocellular carcinoma (HCC) risk in advanced liver fibrosis is urgently needed for cost-effective HCC screening; however, this currently remains an unmet need. Methods: A...
17.
Waghorn P, Ferreira D, Erstad D, Rotile N, Masia R, Jones C, et al.
Sci Rep
. 2021 Mar;
11(1):6105.
PMID: 33731798
Non-alcoholic steatohepatitis (NASH) is an increasing cause of chronic liver disease characterized by steatosis, inflammation, and fibrosis which can lead to cirrhosis, hepatocellular carcinoma, and mortality. Quantitative, noninvasive methods for...
18.
Li S, Saviano A, Erstad D, Hoshida Y, Fuchs B, Baumert T, et al.
J Clin Med
. 2020 Dec;
9(12).
PMID: 33255794
Hepatocellular carcinoma (HCC) is a leading cause of cancer-associated mortality globally. Given the limited therapeutic efficacy in advanced HCC, prevention of HCC carcinogenesis could serve as an effective strategy. Patients...
19.
Ferreira D, Arora G, Gieseck 3rd R, Rotile N, Waghorn P, Tanabe K, et al.
Invest Radiol
. 2020 Oct;
56(4):244-251.
PMID: 33109919
Methods: Three groups of mice that develop either mild type 2 inflammation and fibrosis (wild type), severe fibrosis with exacerbated type 2 inflammation (Il10-/-Il12b-/-Il13ra2-/-), or minimal fibrosis with marked type...
20.
Alsamman S, Christenson S, Yu A, Ayad N, Mooring M, Segal J, et al.
Sci Transl Med
. 2020 Aug;
12(557).
PMID: 32817366
Hepatic stellate cells (HSCs) drive hepatic fibrosis. Therapies that inactivate HSCs have clinical potential as antifibrotic agents. We previously identified acid ceramidase (aCDase) as an antifibrotic target. We showed that...